-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Spyre Therapeutics, Lowers Price Target to $121

Benzinga·08/26/2026 10:01:40
语音播报
BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $132 to $121.